Abstract: The invention relates to process for the preparation of Candesartan cilexetil. More particularly, it relates to the preparation of pure candesartan cilexetil by the deprotection of Trityl candesartan cilexetil with inorganic acids.
FORM-2
THE PATENTS ACT, 1970 (39 of 1970)
COMPLETE SPECIFICATION
(See section 10, rule 13)
1. Title of the invention.
“An Improved process for the preparation of Candesartan Cilexetil”
2. Applicant: MATRIX LABORATORIES LTD
3. Address: MATRIX LABORATORIES LTD,
1-1-151/1, IV FLOOR,
SAIRAM TOWERS, ALEXANDER ROAD,
SECUNDERABAD, 500003
INDIA
The Following specification describes the nature of this invention (and the manner in which it is to be performed).
1
Field of the Invention:
The present invention relates to process for preparation of candesartan cilexetil by detrytilation of Trityl candesartan cilexetil using the inorganic acids.
Background of the Invention:
Candesartan cilexetil, l-[[(Cyclohexyloxy) carbonyl] oxy] ethyl-2-ethoxy-l-[[2'-(lH-tetrazol-5-yl) 1,1 '-biphenyl-4-yl]methyl]-1 H-benzimidazole-7-carboxylate (Candesartan cilexetil) has the formula as given below
Candesartan cilexetil
Candesartan is a potent, selective ATI subtype angiotensin II receptor antagonist and used for treatment of hypertension. Due to poor absorption of Candesartan in body, the prodrug candesartan cilexetil was developed. The candesartan cilexetil is rapidly and completely hydrolyzed to candesartan in gastrointestinal tract.
U.S. Pat. No. 5,196,444 discloses Candesartan cilexetil and a process for its preparation by the reaction of 2-ethoxy-[[2'-(lH-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid with trityl chloride in presence of triethyl amine in methylene chloride, purification by column chromatography gives 2-ethoxy-1 -[[2'»(N-triphenylmethyltetrazol-5-yl)-biphenyl-4-yl]methyl] benzimidazole -7-carboxylic acid, which upon condensation with cyclohexyl 1-iodoethyl carbonate in presence of potassium carbonate in DMF followed by purification with column chromatography
2
gives a colorless powder which is recrystallized in ethanol yields 'C type crystals of Candesartan cilexitil.
U.S. Pat. Application No. 2005/131027 discloses a process for preparation of candesartan cilexetil by reaction of trityl candesartan with cilexetil halide and at least one base in a low boiling solvent in presence of phase transfer catalyst to give Trityl candesartan cilexetil, which upon deprotection with at least one organic acid in at least one organic solvent. U.S. Pat. Application 2005/131027 further discloses the deprotection of Trityl candesartan cilexetil in methanol without an acid.
The PCT publication WO 2005/021535 discloses the deprotection of Trityl candesartan cilexetil with neutral or slightly basic medium in alcohol.
The prior art disclosed methods for preparation of Candesartan cilexetil involves purification of Trityl candesartan and Candesartan cilexetil by column chromatography or involves the use of strong acids like IN HC1 or the use of organic acids or without an acid in methanol for deprotection of Trityl candesartan cilexetil.
There is a requirement of a process for preparation of Candesartan cilexetil which yields a pure Candesartan cilexetil without involving the purification by column chromatography and avoid the usage of strong acids for deprotection.
Summary of the invention:
The main object of the invention is to develop a process for the preparation of Candesartan cilexetil from Candesartan through Trityl candesartan and Trityl candesartan cilexetil without involving the purification by column chromatography and deprotection of Trityl candesartan cilexetil with inorganic acids.
3
Detailed description of the invention:
Thus in accordance with the present invention preparation of Candesartan cilexetil comprises the following steps;
- Treating Candesartan with trityl chloride to get Trityl candesartan
- Reacting Trityl candesartan with cilexetil chloride to afford Trityl candesartan
cilexetil
- Deprotecting Trityl candesartan cilexetil to get Candesartan cilexetil
- Recrystallizing Candesartan cilexetil in a mixture of acetone and water to get
type-C crystals
In a specific embodiment, the present invention provides a process for the preparation of Candesartan cilexitil, which involves
• Dissolving Candesartan in methylene chloride
• Adding an organic base preferably triethyl amine
• Adding trityl chloride slowly at room temperature
• Maintaining the reaction mass at reflux temperature for about 1.5 to 3 hrs
• Cooling the reaction mass to 25 to 35°C5 and washing the reaction mass with water
• Separating the layers and concentrating the separated organic layer.
• Adding Ethyl acetate to the residue;
• Raising the temperature of the suspension and maintaining at about 45 to 80°C for
about 30 min to 4hrs.
• Cooling the reaction mass to a temperature of about 0 to 20°C and maintaining for
about 30 min to 6 hrs
• Isolating the product, washing the wet cake with chilled ethyl acetate and drying to
get Trityl candesartan.
Further conversion of Trityl candesartan to Trityl candesartan cilexitil is carried out by Suspending Trityl candesartan in DMSO
4
- Adding inorganic base selected from potassium carbonate, potassium iodide,
sodium carbonate and sodium iodide
- Adding Cilexetil chloride slowly over a period of 15 min to 2hrs at a temperature
of about 45°C to 75°C, preferably at 55°C to 70°C.
- Maintaining the reaction mass at a temperature of about 50°C to 75°C for about 1
hr to 3 hrs
- Adding water and water immiscible hydrocarbon selected from toluene, heptane
Separating the layers and extracting the aq.layer with hydrocarbon selected from
toluene, heptane
- Combining the organic layer and removing the solvent under vacuum preferably
at temperature of below 75°C
- Adding ethanol to the residue and isolating the trityl candesartan cilexetil.
However, where the intermediate trityl candesartan cilexetil is not isolated the suspension is proceeded directly for the deprotection reaction.
Deprotection of trityl candesartan cilexitil is carried out by
• Suspending Trityl cilexetil candesartan in ethanol
• Adding inorganic acid(s) selected from phosphoric acid, boric acid
• Maintaining the reaction mass at a temperature of 45°C to reflux temperature for a
period for about 6 hrs to 16 hrs
• Concentrating the reaction mass to about 1/2 to 1/4 volume of original volume,
• Adding an antisolvent selected from the group C5 - C7 hydrocarbon preferably
hexane and Heptane at temperature of 20°C to 65°C
• Maintaining the mass for about 1 hr to 12 hrs at temperature of 10°C to 55°C
preferably at about 15°C to 30°C to get Candesartan cilexitil.
The above obtained Candesartan cilexetil can be converted to stable Type-C crystals by the prior art methods or by the method given below.
• Dissolving candesartan cilexetil in acetone at a temperature of 45°C to 60°C,
5
• Removing the insolubles,
• Adding water preferably in lots, first lot at a temperature of about 35°C to 45°C
and 2nd lot at a temperature of 20°C to 35°C and maintaining for about 2hrs to 6
hrs at room temperature
• Isolating the product and wash the wet cake with aq acetone
• Drying the product under vacuum at temperature preferably at about 45°C to 65°C
to get the Type-C crystals of Candesartan cilexetil.
The obtained type-C crystals are identified by its IR, XRD data.
Methods known in the art may be used with the process of this invention to enhance any aspect of this process. For example the product obtained may be further purified by crystallization from solvent(s). The present invention is further illustrated by the following examples, which are provided nearly to the exemplary of the inventions and is not intended to limit the scope of invention. Certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included with in the scope of the present invention in any way.
Example-1: Preparation of Candesartan cilexetil (with isolation of Trityl Candesartan Cilexetil)
Step-I: Preparation of Trityl candesartan
To solution of Candesartan (l00g in 350 ml MDC) and triethyl amine (34.3 g) Trityl chloride (76.8g in 150 ml MDC) is added slowly at temperature of 25 - 30°C. Temperature of the reaction mass is raised and maintained at reflux temperature for 2 hrs. Reaction mass is cooled to temperature of 30 - 35°C, water (100 ml) is added, stirred for about 15 min, allowed to settle and separated the layers. Aqueous layer is extracted with MDC (2x 100 ml), combined organic layer is washed with water and MDC is removed below 50°C from organic layer. Ethyl acetate (600 ml) is added, raised and maintained the temperature of the reaction mass at reflux temperature for 2hrs. The temperature of the mass is cooled, maintained for 1 hr at 25 - 30°C and isolated the product by filtration.
6
Example-1: Preparation of Candesartan cilexetil (with isolation of cilexetil trityl candesartan)
Step-I: Preparation of Trityl candesartan
To solution of Candesartan (l00g in 350 ml MDC) and triethyl amine (34.3 g) Trityl chloride (76.8g in 150 ml MDC) is added slowly at temperature of 25 - 30°C. Temperature of the reaction mass is raised and maintained at reflux temperature for 2 hrs. Reaction mass is cooled to temperature of 30 - 35°C, water (100 ml) is added, stirred for about 15 min, allowed to settle and separated the layers. Aqueous layer is extracted with MDC (2x 100 ml), combined organic layer is washed with water and MDC is removed below 50°C from organic layer. Ethyl acetate (600 ml) is added, raised and maintained the temperature of the reaction mass at reflux temperature for 2hrs. The temperature of the mass is cooled, maintained for 1 hr at 25 - 30°C and isolated the product by filtration. Wet cake is washed with ethyl acetate (100 ml) and dried at temperature of 45 - 50°C to constant weight.
The weight of trityl candesartan is 130 g (Yield 83.8%) Step-2: Preparation of Trityl candesartan cilexetil
Carbohexyl 1-chloroethyl carbonate (36 g) is added to a suspension of trityl candesartan (100 g), potassium carbonate (24 g) and potassium iodide (12 g) in DMSO (500 ml) at temperature of 60 - 65°C over 30 min. Reaction mass is maintained at 60-65°C for 2 hrs, added toluene (300 ml) and water (300 ml). Reaction mass is mixed for 15 min., allowed to settle, the layers are separated at 60 - 65°C and aqueous layer is extracted with toluene (200 ml). Water (200 ml) washings are given to the combined organic layer and toluene extractions twice at temperature of 60 - 65°C. Toluene is distilled off from water washed organic layer at temperature below 60°C under vacuum, ethanol (100 ml) is added, mixed for about 30 min and distilled off solvents under vacuum at temperature below 60°C under vacuum. Residue is cooled to 30 - 35°C, ethanol (300 ml) is added, mixed for 2 hrs at 25 -30°C and filtered the product. Wet cake is washed with ethanol (100 ml) and suck dried.
Wet weight of Cilexetil trityl candesartan is 180 g
Example 2; Preparation of Candesartan cilexetil (without isolation of Trityl Candesartan Cilexetil)
Carbohexyl 1-chloroethyl carbonate (36 g) is added to a suspension of trityl candesartan (100 g), potassium carbonate (24 g) and potassium iodide (12 g) in DMSO (500 ml) at temperature of 60 - 65°C over 30 min. Reaction mass is maintained at 60-65°C for 2 hrs, added toluene (300 ml) and water (300 ml). Reaction mass is mixed for 15 min., allowed to settle, the layers are separated at 60 - 65°C and aqueous layer is extracted with toluene (200 ml). Water (200 ml) washings are given to the combined organic layer and toluene extractions twice at temperature of 60 - 65°C. Toluene is distilled off from water washed organic layer at temperature below 60°C under vacuum, ethanol (100 ml) is added, mixed for about 30 min and distilled off solvents under vacuum at temperature below 60°C under vacuum. Residue is cooled to 30 - 35°C, ethanol (1000ml) and boric acid (9.0 g) is added at temperature of 25 - 30°C, temperature of reaction mass is raised and maintained at reflux temperature for 8 hrs. Reaction mass is concentrated to one third of its original volume by distillation of solvent and cooled the solution to 25 - 30°C.
n-Hexane (500 ml) is added to the reaction mass, mixed for 8hrs at 25 - 30°C and filtered the product. Wet cake is slurry washed with mixture of acetone, water ( 6:4, 100 ml) and dried the material at temperature of 45-50°C till becomes constant weight.
Dry weight of Candesartan Cilexetil is 65 g (Yield: 72.5%)
Example 3: Preparation of crystalline Type-C Candesartan Cilexetil
Candesartan Cilexetil (100 g) is suspended in acetone (600 ml), temperature is raised and maintained at reflux temperature for 30 min. Cooled the reaction mass to 40 - 45°C and filtered the mass to remove insolubles. Water (120 ml) is added slowly over 30 min at 40 - 45°C, gradually cooled the mass to 25 - 30°C and water (120 ml) is added slowly over 30 min at 25 - 30°C. Reaction mass is maintained at temperature of 25-30°C for 4 hrs, filtered the product, washed the wet cake with a mixture of acetone: water (100:40) and
dried the wet cake at temperature of 45 - 50°C under vacuum till becomes constant weight.
Dry weight of Crystalline Type-C Candesartan Cilexetil is 90 g (Yield: 90 %) The crystallinity is identified by its XRD pattern.
| Section | Controller | Decision Date |
|---|---|---|
| # | Name | Date |
|---|---|---|
| 1 | 250-CHE-2006 FORM-18 16-10-2009.pdf | 2009-10-16 |
| 1 | 250-CHE-2006-RELEVANT DOCUMENTS [07-05-2021(online)].pdf | 2021-05-07 |
| 2 | 250-CHE-2006 FORM-13 30-11-2010.pdf | 2010-11-30 |
| 2 | 250-CHE-2006-RELEVANT DOCUMENTS [30-03-2020(online)].pdf | 2020-03-30 |
| 3 | 250-CHE-2006-RELEVANT DOCUMENTS [20-03-2019(online)].pdf | 2019-03-20 |
| 3 | 250-che-2006-form3.pdf | 2011-09-02 |
| 4 | 250-CHE-2006-IntimationOfGrant18-07-2018.pdf | 2018-07-18 |
| 4 | 250-che-2006-form1.pdf | 2011-09-02 |
| 5 | 250-CHE-2006-PatentCertificate18-07-2018.pdf | 2018-07-18 |
| 5 | 250-che-2006-description(complete).pdf | 2011-09-02 |
| 6 | Abstract_Granted 298932_18-07-2018.pdf | 2018-07-18 |
| 6 | 250-che-2006-correspondence-others.pdf | 2011-09-02 |
| 7 | Claims_Granted 298932_18-07-2018.pdf | 2018-07-18 |
| 7 | 250-che-2006-claim.pdf | 2011-09-02 |
| 8 | Description_Granted 298932_18-07-2018.pdf | 2018-07-18 |
| 8 | 250-che-2006-abstract.pdf | 2011-09-02 |
| 9 | 250-che-2006 form-3.pdf | 2011-09-02 |
| 9 | Marked up Claims_Granted 298932_18-07-2018.pdf | 2018-07-18 |
| 10 | 250-che-2006 correspondance others.pdf | 2011-09-02 |
| 10 | 250-CHE-2006-Written submissions and relevant documents (MANDATORY) [05-07-2018(online)].pdf | 2018-07-05 |
| 11 | 250-CHE-2006 FORM-3 09-09-2011.pdf | 2011-09-09 |
| 11 | 250-CHE-2006-Written submissions and relevant documents (MANDATORY) [02-07-2018(online)].pdf | 2018-07-02 |
| 12 | 250-CHE-2006-HearingNoticeLetter.pdf | 2018-06-07 |
| 12 | Form13_Name Of Applicant Change_30-11-2011.pdf | 2011-11-30 |
| 13 | 250-CHE-2006-COMPLETE SPECIFICATION [05-01-2018(online)].pdf | 2018-01-05 |
| 13 | Form13_Address Of Service Change_30-11-2011.pdf | 2011-11-30 |
| 14 | 250-CHE-2006 OTHER PATENT DOCUMENT 23-05-2013.pdf | 2013-05-23 |
| 14 | 250-CHE-2006-FER_SER_REPLY [05-01-2018(online)].pdf | 2018-01-05 |
| 15 | 250-CHE-2006 FORM-3 23-05-2013.pdf | 2013-05-23 |
| 15 | 250-CHE-2006-FER.pdf | 2017-07-10 |
| 16 | 250-CHE-2006 CORRESPONDENCE OTHERS 23-05-2013.pdf | 2013-05-23 |
| 16 | 250-CHE-2006-Form-13-301110.pdf | 2016-10-17 |
| 17 | 250-CHE-2006-Form-13-301110.pdf | 2016-10-17 |
| 17 | 250-CHE-2006 CORRESPONDENCE OTHERS 23-05-2013.pdf | 2013-05-23 |
| 18 | 250-CHE-2006 FORM-3 23-05-2013.pdf | 2013-05-23 |
| 18 | 250-CHE-2006-FER.pdf | 2017-07-10 |
| 19 | 250-CHE-2006 OTHER PATENT DOCUMENT 23-05-2013.pdf | 2013-05-23 |
| 19 | 250-CHE-2006-FER_SER_REPLY [05-01-2018(online)].pdf | 2018-01-05 |
| 20 | 250-CHE-2006-COMPLETE SPECIFICATION [05-01-2018(online)].pdf | 2018-01-05 |
| 20 | Form13_Address Of Service Change_30-11-2011.pdf | 2011-11-30 |
| 21 | 250-CHE-2006-HearingNoticeLetter.pdf | 2018-06-07 |
| 21 | Form13_Name Of Applicant Change_30-11-2011.pdf | 2011-11-30 |
| 22 | 250-CHE-2006 FORM-3 09-09-2011.pdf | 2011-09-09 |
| 22 | 250-CHE-2006-Written submissions and relevant documents (MANDATORY) [02-07-2018(online)].pdf | 2018-07-02 |
| 23 | 250-che-2006 correspondance others.pdf | 2011-09-02 |
| 23 | 250-CHE-2006-Written submissions and relevant documents (MANDATORY) [05-07-2018(online)].pdf | 2018-07-05 |
| 24 | Marked up Claims_Granted 298932_18-07-2018.pdf | 2018-07-18 |
| 24 | 250-che-2006 form-3.pdf | 2011-09-02 |
| 25 | Description_Granted 298932_18-07-2018.pdf | 2018-07-18 |
| 25 | 250-che-2006-abstract.pdf | 2011-09-02 |
| 26 | Claims_Granted 298932_18-07-2018.pdf | 2018-07-18 |
| 26 | 250-che-2006-claim.pdf | 2011-09-02 |
| 27 | Abstract_Granted 298932_18-07-2018.pdf | 2018-07-18 |
| 27 | 250-che-2006-correspondence-others.pdf | 2011-09-02 |
| 28 | 250-CHE-2006-PatentCertificate18-07-2018.pdf | 2018-07-18 |
| 28 | 250-che-2006-description(complete).pdf | 2011-09-02 |
| 29 | 250-CHE-2006-IntimationOfGrant18-07-2018.pdf | 2018-07-18 |
| 29 | 250-che-2006-form1.pdf | 2011-09-02 |
| 30 | 250-CHE-2006-RELEVANT DOCUMENTS [20-03-2019(online)].pdf | 2019-03-20 |
| 30 | 250-che-2006-form3.pdf | 2011-09-02 |
| 31 | 250-CHE-2006 FORM-13 30-11-2010.pdf | 2010-11-30 |
| 31 | 250-CHE-2006-RELEVANT DOCUMENTS [30-03-2020(online)].pdf | 2020-03-30 |
| 32 | 250-CHE-2006 FORM-18 16-10-2009.pdf | 2009-10-16 |
| 32 | 250-CHE-2006-RELEVANT DOCUMENTS [07-05-2021(online)].pdf | 2021-05-07 |
| 1 | 250_18-10-2016.pdf |